Optimal medical treatment of cardiovascular risk factors: Can we prevent the development of heart failure?

Expert Review of Cardiovascular Therapy

Volumn 7, Issue 2, 2009, Pages 147-157

  Alba, Ana C ^a   Delgado, Diego H ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Coronary heart disease; Diabetes; Dyslipidemia; Heart failure; Hypertension; Metabollic syndrome; Obesity; Prevention; Risk factor; Treatment

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; METFORMIN; METOPROLOL; PLACEBO; PRAVASTATIN; RAMIPRIL; ROSUVASTATIN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY RISK; DIABETES MELLITUS; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DYSLIPIDEMIA; FLUID RETENTION; HEART FAILURE; HOSPITALIZATION; HUMAN; HYPERTENSION; INCIDENCE; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; MORTALITY; OBESITY; PREVALENCE; REVIEW; SIDE EFFECT; SURVIVAL; HEART INFARCTION; PATHOPHYSIOLOGY; RISK FACTOR;

CORONARY DISEASE; DISEASE PROGRESSION; DYSLIPIDEMIAS; HEART FAILURE; HUMANS; HYPERTENSION; METABOLIC SYNDROME X; MYOCARDIAL INFARCTION; OBESITY; PREVALENCE; RISK FACTORS;

EID: 64749099589     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.7.2.147     Document Type: Review

References (89)

1. Hunt SA, Antman EM, Smith SC et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure), developed in Collaboration With the American College of Chest Physicians and the International Society for Heart and Lung Transplantation, endorsed by the Heart Rhythm Society. Circulation 112(12), E154-E235 (2005).
2. Felker GM, Shaw LK, O'Connor CM. A standardized definition of ischemic cardiomyopathy for use in clinical research. J. Am. Coll. Cardiol. 39, 210-218 (2002).
3. Kenchaiah S, Narula J, Vasan RS. Risk factors for heart failure. Med. Clin. N. Am. 88, 1145-1172 (2004).
4. Repetto A, Dal Bello B, Pasotti M et al. Coronary atherosclerosis in end-stage idiopathic dilated cardiomyopathy: an innocent bystander? Eur. Heart J. 16, 1519-1527 (2005).
5. Rosamond W, Flegal K, Furie K et al. Heart direase and stroke statistics 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117, E25-E146 (2008).
6. Chow CM, Donovan L, Manuel D, Johasen H, Tu JV. Regional variation in self-reported heart disease prevalence in Canada. Can. J. Cardiol. 21, 1265-1271 (2005).
7. Lloyd-Jones DM, Leip EE, Larson MG et al. Prediction of lifetime risk for. cardiovascular disease by risk factor burden at 50 years of age. Circulation 113, 791-798 (2006).
8. Wilhelmsen L, Rosengren A, Eriksson H, Lappas G. Heart failure in the general population of men-morbidity, risk factors and prognosis. J. Intern. Med. 249, 253-261 (2001).
9. Wolf-Maier K, Cooper RS, Banegas JR et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 289(18), 2363-2369 (2003).
10. Schargrodsky H, Hernández-Hernández R, Marcet Champagne B et al. CARMELA: assessment of cardiovascular risk in seven Latin American cities. Am. J. Med. 121, 58-65 (2008).
11. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J. Am. Coll. Cardiol. 32(A), 6A-13A (1993).
12. Vasan RS, Beiser A, Seshadri S et al. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA 287(8), 1003-1010 (2002).
13. Lloyd-Jones DM, Larson MG, Leip EP et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 106, 3068-3072 (2002).
14. Owan TE, Redfield MM. Epidemiology of diastolic heart failure. Prog. Cardiovasc. Dis. 47, 320-332 (2005).
15. Levy D, Garrison RJ, Savage DD et al. Left ventricular mass as incidence of coronary heart disease in an elderly cohort: the Framingham study. Ann. Intern. Med. 110, 101-107 (1989).
16. Weber KT, Brilla CG, Campbell SE, Zhou G, Matsubara L, Guarda E. Pathologic hypertrophy with fibrosis: the structural basis for myocardial failure. Blood Press. 1, 75-85 (1992).
17. Vasan RS, Levy D. The role of hypertension in the pathogenesis of heart failure: a clinical mechanistic overview. Arch. Intern. Med. 156(16), 1789-1796 (1996).
18. Domanski M, Mitchell G, Pfeffer M et al. Pulse pressure and cardiovascular disease-related mortality: follow-up study of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 287(20), 2677-2683 (2002).
19. Lanas F, Avexam A, Bautista LE et al. Risk factors for acute myocardial infarction in latin america: the INTERHEART Latin American study. Circulation 115, 1067-1074 (2007).
20. Moser M, Herbert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J. Am. Coll. Cardiol. 27(5), 1214-1218 (1996).
21. Verdecchia P, Angeli F, Borgioni C et al. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am. J. Hypertens. 16, 895-899 (2003).
22. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment of left ventricular mass in essential hypertension. Am. J. Med. 115, 41-46 (2003).
23. Bangalore S, Wild D, Parkar S, Kukin M, Messerli FH. β-blockers for primary prevention of heart failure in patients with hypertension. J. Am. Coll. Cardiol. 52, 1062-1072 (2008).
24. Kaplan NM. β-blockers in hypertension. Adding insult to injury. J. Am. Coll. Cardiol. 52, 1490-1491.
25. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 362, 1527-1535 (2003).
26. Meissner I, Whisnant JP, Sheps SG et al. Detection and control of high blood pressure in the community: do we need a wake-up call? Hypertension 34, 466-471 (1999).
27. Chobanian AC, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42, 1206-1252 (2003).
28. Haffiner SM, Lehto S, Ronnemaa T et al. Mortality from coronary heart disease in subjects with Type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 339, 229-234 (1998).
29. Adams KF Jr, Fonarow GC, Emerman CL et al.; ADHERE Scientific Advisory Committee and Investigators. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am. Heart J. 149, 209-216 (2005).
30. 1c with cardiovascular disease and mortality in adults. The European prospective investigation into cancer in Norfolk. Ann. Intern. Med. 141, 413-420 (2004).
31. Iribarren C, Karter AJ, Go AS et al. Glycemic control and heart failure among adult patients with diabetes. Circulation 21, 2668-2673 (2001).
32. Stratton IM, Adler AI, Neil HA et al. Association of glycemia with macrovascular and microvascular complications of Type 2 diabetes (UKPDS 35); prospective observational study. BMJ 321, 405-412 (2000).
33. Kamalesh M. Heart failure in diabetes and related conditions. J. Cardiac Fail. 13, 861-873 (2007).
34. Bell DSH. Hypertension in the person with diabetes. Am. J. Med. Sci. 297, 228-232 (1989).
35. Bell DSH. Diabetic-hypertensive pre-heart failure patient. Heart Failure Clin. 2(1), 13-16 (2006).
36. Struthers AD, Morris AD. Screening for and treating left-ventricular abnormalities in diabetes mellitus: a new way of reducing cardiac deaths. Lancet 559, 1430-1432 (2002).
37. Devereux RB, Roman MJ, Paranicas M et al. Impact of diabetes on cardiac structure and function: the Strong Heart study. Circulation 101, 2271-2276 (2000).
38. Boyd A, Nawarskas J. Metformin use in decompensated heart failure. Cardiol. Rev. 16, 269-272 (2008).
39. Tang, WH, Francis GS, Hoogwerf BJ, Young JB. Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. J. Am. Coll. Cardiol. 41, 1394-1398 (2003).
40. Wang CH, Weisel RD, Liu PP, Fedak PW, Verma S. Glitazones and heart failure: critical appraisal for the clinician. Circulation 107, 1350-1354 (2003).
41. Masoudi FA, Inzucchi SE, Wang Y et al. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 111, 583-590 (2005).
42. Aguilar D, Bozkurt B, Pritchett A et al. The impact of thiazolidinedione use on outcomes in ambulatory patients with diabetes mellitus and heart failure. J. Am. Coll. Cardiol. 50, 32-36 (2007).
43. Leier CV, Haas GJ. Diabetes and heart failure: the role of thiazolidinediones in managing these partners in crime. J. Am. Coll. Cardiol. 50, 37-39 (2007).
44. Abuissa H, Jones PG, Marso SP, O'Keefe JH Jr. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of Type 2 diabetes: a meta-analysis of randomized clinical trials. J. Am. Coll. Cardiol. 46, 821-826 (2005).
45. The DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N. Engl. J. Med. 355, 1551-1562 (2006).
46. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for Type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N. Engl. J. Med. 342, 905-912 (2000).
47. Holzgreve H, Nakov R, Beck K, Janka HU. Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control. Am. J. Hypertens. 5, 381-386 (2003).
48. Bakris GL, Fonseca V, Katholi RE et al.; GEMINI Investigators. Metabolic effects of carvedilol versus metoprolol in patients with Type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 292, 2227-2236 (2004).
49. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 288, 1723-1727 (2002).
50. Wilson PW, D'Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch. Intern. Med. 162, 1867-1872 (2002).
51. Kenchaiah S, Evans JC, Levy D et al. Obesity and the risk of heart failure. N. Engl. J. Med. 347, 305-313 (2002).
52. Massie BM. Obesity and heart failure - risk factor or mechanism? N. Engl. J. Med. 347, 358-359 (2002).
53. Abdulla J, Kober L, Abildstrom SZ, Christensen E, James WP, Torp-Pedersen C. Impact of obesity as a mortality predictor in high-risk patients with myocardial infarction or chronic heart failure: a pooled analysis of five registries. Eur. Heart J. 29, 594-601 (2008).
54. Balkau B, Deanfield JE, Després JP et al. International Day for the Evaluation of Abdominal obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168, 000 primary care patients in 63 countries. Circulation 116, 1942-1951 (2007).
55. Jensen MK, Chiuve SE, Rimm EB et al. Obesity, behavioral lifestyle factors, and risk of acute coronary events. Circulation 117, 3062-3069 (2008).
56. Slentz CA, Duscha BD, Johnson JL et al. Effects of the amount of exercise on body weight, body composition, and measures of central obesity: STRRIDE - a randomized controlled study. Arch. Intern. Med. 164, 31-39 (2004).
57. Laaksonen DE, Lakka HM, Niskanen LK, et al. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am. J. Epidemiol. 156, 1070-1077 (2002).
58. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among us adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287, 356-359 (2002).
59. Lee ET, Cowan LD, Welty TK et al. All-cause mortality and cardiovascular disease mortality in three American - Indian populations, aged 45-74 years, 1984-1988. The Strong Heart Study. Am. J. Epidemiol. 147(11), 995-1008 (1998).
60. McNeill AM, Rosamond TO, Girman CJ et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the Atherosclerosis Risk in Communities Study. Diabetes Care 28, 385-390 (2005).
61. Butler J, Rodondi N, Zhu Y et al. Metabolic syndrome and the risk of cardiovascular disease in older adults. J. Am. Coll. Cardiol. 47, 1595-1602 (2006).
62. Zeller M, Steg PG, Ravisy J et al. Prevalence and impact of metabolic syndrome on hospital outcomes in acute myocardial infarction. Arch. Intern. Med. 165, 1192-1198 (2005).
63. Ingelsson E, Arnlov J, Lind L, Sundstrom J. Metabolic syndrome and risk for heart failure in middle-aged men. Heart 92, 1409-1413 (2006).
64. Lakka HM, Lakksonen DE, Lakka TA et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288, 2709-2716 (2002).
65. Hassan SA, Deswal A, Bozkurt B et al. The metabolic syndrome and mortality in an ethnically diverse heart failure population. J. Cardiac Fail. 14, 590-595 (2008).
66. Thethi T, Bratcher C, Fonseca V. Metabolic syndrome and heart failure. Heart Failure Clin. 2(1), 1-11 (2006).
67. Alpert MA. Management of obesity cardiomyopathy. Am. J. Med. Sci. 321, 237-241 (2001).
68. LaMonte MJ, Barlow CE, Jurca R et al. Cardiorespiratory fitness is inversely associated with the incidence of metabolic syndrome: a prospective study of men and women. Circulation 112, 505-512 (2005).
69. Raji A, Seely EW, Bekins SA et al. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 26, 172-178 (2003).
70. Hetzel J, Balletshofer B, Ritting K et al. Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers. Arterioscler. Thromb. Vasc. Biol. 25, 1804-1809 (2005).
71. Henriksen EJ, Jacob S. Modulation of metabolic control by angiotensin converting enzyme (ACE) inhibition. J. Cell. Physiol. 196, 171-179 (2003).
72. 1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J. Am. Coll. Cardiol. 44, 362-368 (2004).
73. Yusuf S, Hawken S, Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364, 937-952 (2004).
74. McPherson R, Frohlich J, Fodor G et al. Canadian Cardiovascular Society position statement: recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can. J. Cardiol. 22, 913-927 (2006).
75. Grundy SM, Cleeman JI, Merz CN et al.; Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 110, 227-239 (2004).
76. De Backer G, Ambrosioni E, Borch-Johnsen K et al. European guidelines on cardiovascular disease and prevention in clinical practice. Third joint task force of European and other societies on cardiovascular disease prevention in clinical practice. Eur. Heart J. 24, 1601-1610 (2003).
77. West of Scotland Coronary Prevention Study Group. A coronary primary prevention study of Scottish men aged 45-64 years: trial design. J. Clin. Epidemiol. 45, 849-860 (1992).
78. West of Scotland Coronary Prevention Study Group. Long-term follow-up of the West of Scotland Coronary Prevention Study. N. Engl. J. Med. 357, 1477-1486 (2007).
79. Hognestad A, Dickstein K, Myhre E, Snapinn S, Kjekshus J. Effect of combined statin and β-blocker treatment on one-year morbidity and mortality after acute myocardial infarction associated with heart failure. Am. J. Cardiol. 93, 603-606 (2004).
80. Josan K, Majumdar SR, McAlister FA. The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials. CMAJ 178(5), 576-584 (2008).
81. Strey CH, Young JM, Lainchbury JH et al. Short-term statin treatment improves endothelial function and neurohormonal imbalance in normocholesterolaemic patients with non-ischaemic heart failure. Heart 92, 1603-1609 (2006).
82. Sola S, Mir MQ, Lerakis S, Tandon N, Khan BV. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J. Am. Coll. Cardiol. 47, 332-337 (2006).
83. Khush KK, Waters DD. Effects of statin therapy on the development and progression of heart failure: mechanisms and clinical trials. J. Card. Fail. 12(8), 664-674 (2006).
84. Khush KK, Waters DD, Bittner V et al.. Effect of high-dose atorvastatin on hospitalizations for heart failure. Subgroup analysis of the Treating to New Targets (TNT) Study. Circulation 115, 576-583 (2007).
85. Shah R, Wang Y, Foody JM. Effect of statins, angiotensin-converting enzyme inhibitors, and β-blockers on survival in patients >65 years of age with heart failure and preserved left ventricular systolic function. Am. J. Cardiol. 101, 217-222 (2008).
86. Rinfret S, Behlouli H, Eisenberg MJ, Humphries K, Tu JV, Pilote L. Class effects of statins in elderly patients with congestive heart failure: a population-based analysis. Am. Heart J. 155, 316-323 (2008).
87. Kjekshus J, Apetrei E, Barrios V et al. Rosuvastatin in older patients with systolic heart failure. N. Engl. J. Med. 357, 2248-2261 (2007).
88. Holdaas H. Statin therapy for prevention of coronary artery disease. The earlier the better or the longer the better? Eur. Heart J. 29, 425-426 (2008).
89. Kannel WB. Lessons from curbing the coronary artery disease for confronting the impending epidemic of heart failure. Med. Clin. N. Am. 88(5), 1129-1133 (2004).